Asymmetric ring-opening reactions of bicyclic alkenes are a significant area of research in organic chemistry, particularly for their ability to produce valuable chiral compounds. These reactions ...

In a breakthrough that challenges long-held conventions in organic synthesis, researchers have successfully created a class ...

School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China ...

Department of Chemistry, Stanford University, 337 Campus Drive, Stanford, California 94305, United States ...

BARCELONA, September 14, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ...

A groundbreaking discovery by researchers at the University of California, Los Angeles (UCLA) has challenged a long-standing ...

Bicycle Therapeutics has developed a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, and will gain funding for phase 1 and phase 1b clinical trial ...

These compounds, characterized by a bicyclic structure that includes a benzene ring fused to a thiazole ring, exhibit a wide range of biological activities. Their versatility makes them valuable ...

The company is developing a new class of drugs based on its proprietary ‘Bicycle’ bicyclic peptide product platform, which aims to combine the best qualities of several therapeutic entities in ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Fifteen of these 76 substances (CAS RNs 80-56-8, 1113-21-9, 8000-46-2, 8002-09-3, 8006-64-2, 8007-01-0, 8007-02-1, 8008-31-9, 8008-52-4, 8008-57-9, 8014-19-5, 8015-77-8, 8016-85-1, 8021-28-1 and ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced updated topline Phase 1 ...